1. Home
  2. SID vs ABUS Comparison

SID vs ABUS Comparison

Compare SID & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Companhia Siderurgica Nacional S.A.

SID

Companhia Siderurgica Nacional S.A.

N/A

Current Price

$0.51

Market Cap

833.8M

Sector

Industrials

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$4.04

Market Cap

836.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SID
ABUS
Founded
1941
2005
Country
Brazil
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
833.8M
836.0M
IPO Year
2002
2008

Fundamental Metrics

Financial Performance
Metric
SID
ABUS
Price
$0.51
$4.04
Analyst Decision
Sell
Analyst Count
4
0
Target Price
★ $1.17
N/A
AVG Volume (30 Days)
★ 10.8M
2.3M
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.26
EPS
N/A
★ 1.13
Revenue
N/A
★ $14,083,000.00
Revenue This Year
N/A
$1,208.75
Revenue Next Year
$1.87
N/A
P/E Ratio
★ N/A
$3.61
Revenue Growth
N/A
★ 128.21
52 Week Low
$0.55
$3.50
52 Week High
$2.20
$5.45

Technical Indicators

Market Signals
Indicator
SID
ABUS
Relative Strength Index (RSI) 24.87 46.55
Support Level N/A $3.59
Resistance Level $1.34 $4.52
Average True Range (ATR) 0.07 0.20
MACD -0.02 0.04
Stochastic Oscillator 1.23 72.58

Price Performance

Historical Comparison
SID
ABUS

About SID Companhia Siderurgica Nacional S.A.

Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations port concessions and fleets of road transport vehicles. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: